<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZAFIRLUKAST <img border="0" src="../images/pr.gif"/></span><br/>(za-fir-lu'kast)<br/><span class="topboxtradename">Accolate<br/></span><b>Classifications:</b> <span class="classification">bronchodilator (respiratory smooth muscle relaxant)</span>; <span class="classification">leukotriene receptor antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Selective peptide leukotriene receptor antagonist (LTRA) of leukotriene D<sub>4</sub> and E<sub>4</sub>, thus inhibiting bronchoconstriction. Leukotriene production and receptor affinity have been correlated with the pathogenesis
         of asthma.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Zafirlukast helps to prevent the signs and symptoms of asthma including airway edema, smooth muscle constriction, and altered
         cellular activity due to inflammation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and chronic treatment of asthma in adults and children &gt;5 y (not for acute bronchospasm).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zafirlukast; acute asthma attacks, including status asthmaticus, acute bronchospasm; lactation, children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment, hepatic disease; patients <img src="../images/special/greaterorequal.gif"/>65 y, pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Asthma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg b.i.d. 1 h before or 2 h after meals<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;<i>5 y</i>, 10 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after meals.</li>
<li>Store at 20°25° C (68°77° F); protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Generalized pain, asthenia, myalgia, fever, back pain. <span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> dizziness. <span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain, vomiting, dyspepsia; liver dysfunction, increased liver function tests, <span class="speceff-life">hepatic failure</span>.  <span class="typehead">Other:</span> <span class="speceff-life">Churg-Strauss syndrome</span> (fever, muscle aches and pains, weight loss). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase prothrombin time (PT) in patients on <b>warfarin.</b> <b>Erythromycin</b> decreases bioavailability of zafirlukast. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, bioavailability significantly reduced by food. <span class="typehead">Onset:</span> 1 wk. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> &gt;99% protein bound; secreted into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver via cytochrome P450 2C9 (CYP2C9) and possibly CYP3A4. <span class="typehead">Elimination:</span> 90% excreted in feces, 10% in urine. <span class="typehead">Half-Life:</span> 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess respiratory status and airway function regularly.</li>
<li>Lab tests: Periodic liver function tests.</li>
<li>Monitor closely PT and INR with concurrent warfarin therapy.</li>
<li>Monitor closely phenytoin level with concurrent phenytoin therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Taking medication regularly, even during symptom-free periods.</li>
<li> 							Note: Drug is not intended to treat acute episodes of asthma. 						</li>
<li>Report S&amp;S of hepatic toxicity (see Appendix F) or flu-like symptoms to physician. Follow-up lab work is very important.</li>
<li>Notify physician immediately if condition worsens while using prescribed doses of all antiasthmatic medications.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>